Products from BPS Bioscience require a minimum order value above 400€
Applications: Screen for novel ligands of LILRB4
Background: Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4 (LILRB4) contains multiple Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIMs). LILRB4 expression on Acute Myeloid Leukemia (AML) cells promotes tumor cell infiltration and suppresses T cell activity. Because LILRB4 is highly expressed on AML cells but not on normal hematopoietic stem cells, LILRB4 has been identified as a promising therapeutic target for CAR-T cells.
Description: Recombinant Jurkat cells constitutively expressing human LILRB4 (Leukocyte Immunoglobulin-Like Receptor Subfamily B Member 4, GenBank Accession #NM_001278426) and the firefly luciferase gene under the control of NFAT response elements.
Host Cell Line: Jurkat
Storage Stability: Immediately upon receipt, store vials in liquid nitrogen.
Supplied As: Each vial contains 2 x 10^6 cells in 1 ml of FBS with 10% DMSO.
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
References: 1. LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration. Deng M, et al. Nature. 2018. 562(7728):605-609.2. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. John S, et al. Mol Ther. 2018. 26(10):2487-2495.
English
Deutsch
